ARID1A loss is a defining genomic alteration in ovarian clear cell carcinoma (OCCC), yet a unifying framework linking its metabolic, transcriptional, and epigenetic processes remains lacking. Here we describe a theoretical model, grounded in verified biochemical pathways, proposing that cellular taurine exclusion represents a major, previously unrecognized metabolic consequence of ARID1A deficiency. We propose that ARID1A contributes to EZH2-mediated silencing of the ABAT gene, which has a noncanonical role in pyrimidine salvage through facilitating dNDP-to-dNTP conversion. The pyrimidine salvage defect caused by ABAT suppression diverts uracil intermediates into degradation, generating excess β-alanine within the cell. β-alanine is proposed to induce long-lived functional inactivation of the cell membrane amino acid transporter TauT, effectively locking it into a near-zero-flux state and driving profound taurine exclusion. Taurine availability modulates expression of the taurine-responsive lncRNA TUG1, which normally sponges PTEN-targeting miRNAs; taurine depletion therefore suppresses TUG1, permitting miRNA-mediated loss of PTEN expression and amplification of PI3K–AKT signaling. This integrated, self-reinforcing metabolo-epigenetic cassette provides a coherent mechanistic explanation for how ARID1A deficiency promotes the proliferative, stress-adapted state characteristic of OCCC, while generating testable predictions and identifying a potentially targetable amino acid–epigenetic axis in ARID1A-deficient cancers.
John Dickason (Tue,) studied this question.